论文部分内容阅读
目的探讨磷霉素联合头孢噻肟钠治疗慢性阻塞性肺疾病合并感染的疗效与安全性。方法磷霉素联合头孢噻肟钠组 3 9例 ,应用磷霉素 4.0 g,静脉滴注 ;1小时后加用头孢噻肟钠 2 .0 g,静滴 ,2次 / d,疗程 7～ 14天。头孢噻肟钠组 40例 ,应用头孢噻肟钠 2 .0 g,静脉滴注 ,2次 / d,疗程 7～ 14天。结果磷霉素联合头孢噻肟钠组的临床痊愈率、有效率和细菌清除率分别为 87.2 %、92 .3 %与 90 .0 % ;头孢噻肟钠组分别为 65 .0 %、72 .5 %和 65 .5 % ;不良反应发生率分别为 7.8%与 5 .0 %。结论磷霉素联合头孢噻肟钠治疗慢性阻塞性肺疾病合并感染 ,其临床治愈率和有效率、细菌清除率等均优于单用头孢噻肟钠。
Objective To investigate the efficacy and safety of fosfomycin plus cefotaxime sodium in the treatment of patients with chronic obstructive pulmonary disease complicated with infection. Methods Fosfomycin combined with cefotaxime sodium 39 cases, application of fosfomycin 4.0 g, intravenous infusion; 1 hour after the addition of cefotaxime sodium 2.0 g, intravenous infusion, 2 times / d, treatment of 7 ~ 14 days. 40 cases of cefotaxime sodium group, the application cefotaxime sodium 2.0 g, intravenous infusion, 2 times / d, treatment of 7 to 14 days. Results The clinical cure rate, effective rate and bacterial clearance rate of fosfomycin plus cefotaxime sodium group were 87.2%, 92.3% and 90.0% respectively, while those in cefotaxime sodium group were 65.0% and 72.0% respectively. 5% and 65.5% respectively. The incidence of adverse reactions were 7.8% and 5.0% respectively. Conclusion Fosfomycin combined with cefotaxime sodium in the treatment of chronic obstructive pulmonary disease complicated with infection, the clinical cure rate and effective rate, bacterial clearance rates were better than single cefotaxime sodium.